CRISPR Therapeutics (CRSP) reported second-quarter 2026 total revenue of $10.2 million and a net loss of $91.2 million for the period ended June 30, 2026. Cash, cash equivalents and marketable securities were $2.36 billion as of June 30, compared with $1.98 billion at the end of 2025.
The company said CASGEVY generated $76 million in second-quarter revenue, up 78% quarter over quarter and 151% year over year. CRISPR Therapeutics also highlighted FDA approval of CASGEVY for children as young as 2 and the initiation of Phase 1 trials for CTX340 and CTX460.
- Total revenue was $10.2 million, compared with $0.9 million in the year-earlier quarter.
- Net loss was $91.2 million, compared with a net loss of $208.5 million in the second quarter of 2025.
- R&D expenses were $67.2 million, compared with $69.9 million a year earlier.
- General and administrative expenses were $17.6 million, compared with $18.9 million a year earlier.
- CASGEVY is approved in 39 countries across North America, Europe and the Middle East.
$CRSP Insider Trading Activity
$CRSP insiders have traded $CRSP stock on the open market 13 times in the past 6 months. Of those trades, 0 have been purchases and 13 have been sales.
Here’s a breakdown of recent trading of $CRSP stock by insiders over the last 6 months:
- SAMARTH KULKARNI (Chief Executive Officer) has made 0 purchases and 4 sales selling 37,134 shares for an estimated $1,851,837.
- RAJU PRASAD (Chief Financial Officer) has made 0 purchases and 3 sales selling 13,577 shares for an estimated $649,738.
- JAMES R. KASINGER (General Counsel and Secretary) has made 0 purchases and 4 sales selling 11,544 shares for an estimated $574,239.
- NAIMISH PATEL (Chief Medical Officer) has made 0 purchases and 2 sales selling 6,936 shares for an estimated $362,596.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$CRSP Hedge Fund Activity
We have seen 218 institutional investors add shares of $CRSP stock to their portfolio, and 179 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL WORLD INVESTORS added 4,725,037 shares (+inf%) to their portfolio in Q1 2026, for an estimated $224,770,010
- CAPITAL INTERNATIONAL INVESTORS removed 4,705,951 shares (-79.9%) from their portfolio in Q1 2026, for an estimated $223,862,089
- TWO SIGMA INVESTMENTS, LP added 1,012,430 shares (+215.1%) to their portfolio in Q1 2026, for an estimated $48,161,295
- UBS GROUP AG removed 761,614 shares (-30.2%) from their portfolio in Q1 2026, for an estimated $36,229,977
- SQUAREPOINT OPS LLC removed 427,533 shares (-73.6%) from their portfolio in Q1 2026, for an estimated $20,337,744
- DIMENSIONAL FUND ADVISORS LP removed 412,889 shares (-45.5%) from their portfolio in Q1 2026, for an estimated $19,641,129
- MILLENNIUM MANAGEMENT LLC added 346,686 shares (+1137.0%) to their portfolio in Q1 2026, for an estimated $16,491,853
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
